|
|
Volumn 31, Issue 33, 2013, Pages 4271-
|
|
Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: Ethical lessons not learned from Africa
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LAPATINIB;
PACLITAXEL;
PLACEBO;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
QUINAZOLINE DERIVATIVE;
TUMOR MARKER;
ADD ON THERAPY;
AFRICA;
BREAST METASTASIS;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
DEVELOPED COUNTRY;
HEALTH CARE QUALITY;
HUMAN;
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE METASTATIC BREAST CANCER;
LETTER;
MARKETING;
MEDICAL ETHICS;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
VULNERABLE POPULATION;
BREAST TUMOR;
DRUG ANTAGONISM;
FEMALE;
METABOLISM;
NOTE;
ANTAGONISTS AND INHIBITORS;
BREAST NEOPLASMS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
PACLITAXEL;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
QUINAZOLINES;
RECEPTOR, ERBB-2;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84892845525
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2013.51.0289 Document Type: Letter |
|
Times cited : (2)
|
|
References (8)
|
